| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10157-013-0904-7 |
| P698 | PubMed publication ID | 24198051 |
| P2093 | author name string | Toshihiko Ishimitsu | |
| Akihiko Nagase | |||
| Eri Ohno | |||
| Hiroshi Satonaka | |||
| Nobuyuki Nakano | |||
| Shou Onoda | |||
| Takehiro Ohira | |||
| Yasuhiko Ueno | |||
| P2860 | cites work | Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 |
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease | Q33761680 | ||
| Beneficial cardiovascular pleiotropic effects of statins | Q34327115 | ||
| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial | Q34630074 | ||
| Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis | Q34660044 | ||
| The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis | Q34845107 | ||
| Statins for improving renal outcomes: a meta-analysis | Q36500899 | ||
| Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese | Q36935199 | ||
| Does reversal of oxidative stress and inflammation provide vascular protection? | Q37355471 | ||
| An update on the lipid nephrotoxicity hypothesis | Q37622061 | ||
| Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis | Q37638675 | ||
| Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. | Q37720584 | ||
| Oxidative stress and endothelial dysfunction: therapeutic implications | Q37834017 | ||
| Chronic kidney disease, dyslipidemia, and atherosclerosis | Q37968151 | ||
| Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities | Q37968218 | ||
| Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? | Q37986290 | ||
| Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease | Q38016352 | ||
| Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis | Q38036553 | ||
| Revised equations for estimated GFR from serum creatinine in Japan | Q39513402 | ||
| Effects of hypertension and dyslipidemia on the decline in renal function | Q41668265 | ||
| Effect of lipid reduction on the progression of renal disease: a meta-analysis | Q43514434 | ||
| Cholesterol and the risk of renal dysfunction in apparently healthy men. | Q44521397 | ||
| Pravastatin and cardiovascular risk in moderate chronic kidney disease. | Q46021527 | ||
| The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. | Q46452621 | ||
| The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. | Q46557175 | ||
| Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease | Q46584977 | ||
| The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. | Q46954188 | ||
| Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. | Q51373144 | ||
| Ezetimibe | Q73386043 | ||
| Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria | Q84185917 | ||
| The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD) | Q84696918 | ||
| Evidence-based practice guideline for the treatment of CKD | Q84978295 | ||
| P433 | issue | 5 | |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 704-710 | |
| P577 | publication date | 2013-11-07 | |
| P1433 | published in | Clinical and experimental nephrology | Q26842022 |
| P1476 | title | Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease. | |
| P478 | volume | 18 |
| Q38680372 | Cathepsin L activity correlates with proteinuria in chronic kidney disease in humans |
| Q40955301 | Effects of atorvastatin on oxidative stress in chronic kidney disease |
| Q42361500 | Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor |
| Q54444667 | How does Eucommia leaf extract prevent smooth muscle cell proliferation induced by high-fat diets at the aortic tunica media? |
Search more.